TrueWealth Advisors LLC Makes New $337,000 Investment in Bristol-Myers Squibb (NYSE:BMY)

TrueWealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 4,496 shares of the biopharmaceutical company’s stock, valued at approximately $337,000.

Other large investors have also recently modified their holdings of the company. Mizuho Securities Co. Ltd. lifted its stake in shares of Bristol-Myers Squibb by 239.0% during the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 239 shares during the last quarter. Nauset Wealth Management. LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at about $27,000. Conrad Siegel Investment Advisors Inc. acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at about $28,000. Steward Financial Group LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $29,000. Finally, Horan Securities Inc. acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $29,000. Institutional investors own 73.07% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on BMY. Barclays upped their target price on Bristol-Myers Squibb from $66.00 to $68.00 in a research report on Monday, May 2nd. StockNews.com assumed coverage on Bristol-Myers Squibb in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Morgan Stanley cut their price objective on Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating on the stock in a report on Wednesday, April 6th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $65.00 to $70.00 and gave the company an “equal weight” rating in a report on Tuesday, May 17th. Finally, Truist Financial increased their price objective on Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Moderate Buy” and an average price target of $74.17.

Bristol-Myers Squibb Stock Up 1.6 %

Shares of NYSE BMY opened at $74.81 on Thursday. The company has a market capitalization of $159.27 billion, a price-to-earnings ratio of 26.53, a price-to-earnings-growth ratio of 1.58 and a beta of 0.45. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.32 and a quick ratio of 1.23. The business has a 50-day moving average of $75.48 and a two-hundred day moving average of $72.39. Bristol-Myers Squibb has a 1 year low of $53.22 and a 1 year high of $80.59.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last posted its earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.14. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The business had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.50 billion. During the same period in the previous year, the business earned $1.93 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post 7.46 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 1st. Investors of record on Friday, July 1st will be given a $0.54 dividend. This represents a $2.16 annualized dividend and a yield of 2.89%. The ex-dividend date is Thursday, June 30th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 76.60%.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Sandra Leung sold 65,000 shares of the business’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $74.89, for a total value of $4,867,850.00. Following the transaction, the executive vice president now owns 308,627 shares in the company, valued at approximately $23,113,076.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Bristol-Myers Squibb news, EVP Sandra Leung sold 65,000 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the transaction, the executive vice president now owns 308,627 shares in the company, valued at approximately $23,113,076.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Giovanni Caforio sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $74.04, for a total value of $2,221,200.00. Following the transaction, the chief executive officer now owns 551,104 shares in the company, valued at approximately $40,803,740.16. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

About Bristol-Myers Squibb

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.